Neurocrine Biosciences Inc. (NASDAQ:NBIX) – Research analysts at Oppenheimer Holdings issued their FY2016 earnings estimates for Neurocrine Biosciences in a research report issued on Monday. Oppenheimer Holdings analyst J. Olson expects that the brokerage will post earnings per share of ($1.65) for the year. Oppenheimer Holdings currently has a “Market Perform” rating and a $55.00 target price on the stock. Oppenheimer Holdings also issued estimates for Neurocrine Biosciences’ Q1 2017 earnings at ($0.53) EPS, Q3 2017 earnings at $0.54 EPS, Q4 2017 earnings at ($0.27) EPS and FY2017 earnings at ($0.78) EPS.

A number of other research firms also recently issued reports on NBIX. Needham & Company LLC initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, October 18th. They issued a “buy” rating and a $62.00 target price for the company. BMO Capital Markets reiterated an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. Robert W. Baird reiterated an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday, August 30th. Leerink Swann began coverage on shares of Neurocrine Biosciences in a research note on Tuesday, October 4th. They set an “outperform” rating and a $70.00 price objective for the company. Finally, Citigroup Inc. began coverage on shares of Neurocrine Biosciences in a research note on Tuesday. They set a “market perform” rating and a $55.00 price objective for the company. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $66.92.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Shares of Neurocrine Biosciences (NASDAQ:NBIX) remained flat at $50.31 during midday trading on Thursday. 596,328 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $46.84 and its 200 day moving average price is $48.11. Neurocrine Biosciences has a 12 month low of $31.25 and a 12 month high of $58.46. The firm’s market capitalization is $4.37 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.43) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.14. During the same quarter last year, the business earned ($0.40) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis.

Several hedge funds have recently modified their holdings of NBIX. Price T Rowe Associates Inc. MD boosted its stake in shares of Neurocrine Biosciences by 1.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 9,364,314 shares of the company’s stock worth $474,209,000 after buying an additional 169,460 shares during the period. Perceptive Advisors LLC boosted its stake in Neurocrine Biosciences by 2.8% in the second quarter. Perceptive Advisors LLC now owns 2,797,967 shares of the company’s stock worth $127,167,000 after buying an additional 77,000 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in Neurocrine Biosciences by 6.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,150,949 shares of the company’s stock worth $108,924,000 after buying an additional 136,277 shares during the period. BlackRock Fund Advisors boosted its stake in Neurocrine Biosciences by 3.3% in the third quarter. BlackRock Fund Advisors now owns 2,009,633 shares of the company’s stock worth $101,768,000 after buying an additional 64,921 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Neurocrine Biosciences by 32.8% in the second quarter. Franklin Resources Inc. now owns 1,541,446 shares of the company’s stock worth $70,059,000 after buying an additional 380,841 shares during the period. 96.30% of the stock is currently owned by institutional investors.

In other Neurocrine Biosciences news, insider Malcolm Lloyd-Smith sold 9,000 shares of the stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $50.00, for a total transaction of $450,000.00. Following the sale, the insider now directly owns 9,000 shares of the company’s stock, valued at $450,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Flint Obrien sold 25,000 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $52.84, for a total transaction of $1,321,000.00. Following the sale, the insider now directly owns 30,044 shares in the company, valued at $1,587,524.96. The disclosure for this sale can be found here. 4.80% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences Inc. (NBIX) to Post FY2016 Earnings of ($1.65) Per Share, Oppenheimer Holdings Forecasts” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/24/neurocrine-biosciences-inc-nbix-to-post-fy2016-earnings-of-1-65-per-share-oppenheimer-holdings-forecasts.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.